Epidermal Growth Factor Inhibitor-induced Cutaneous Toxicity Improves with Moisturizers

2020 ◽  
Vol 4 (1) ◽  
Author(s):  
Ichiko Morino ◽  
Aika Okuno ◽  
Yuka Hirakawa ◽  
Yumiko Saya ◽  
Yumi Murakami ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Normal Skin ◽  
Treatment Options ◽  
Egfr Inhibitors ◽  
Therapeutic Effects ◽  
Cutaneous Toxicity ◽  
Skin Cream ◽  
Epidermal Growth

Although epidermal growth factor receptor (EGFR) inhibitors are one of the most effective treatment options for lung cancer, they frequently cause cutaneous toxicity that can lead to treatment discontinuation. Dryness, which is a common form of cutaneous toxicity, is usually treated using medical moisturizing agents. We aimed to investigate the treatment of cutaneous toxicity caused by EGFR inhibitors by comparing patients who used a cosmetic moisturizer with those who used conventional medical moisturizers. This study included 12 patients with lung cancer, who were receiving EGFR inhibitors and using topical medical moisturizers. The participants were assigned to a group that continued using medical moisturizers or a group that began using NOV® skin cream D. The study’s findings showed that like conventional medical moisturizers, NOV®skin cream D improved the cutaneous dryness caused by EGFR inhibitors and that it might additionally improve patients’ quality of life. Also, we obtained novel findings that NOV® skin cream D normalized keratinization, which is a component of normal skin cell differentiation impeded by EGFR inhibitors. Hence, the cosmetic moisturizer may help to prevent the discontinuation of EGFR inhibitors, thereby ensuring their continuous therapeutic effects.

scholarly journals Epidermal Growth Factor Inhibitor-induced Cutaneous Toxicity Improves with Moisturizers

2020 ◽  
Vol 4 (2) ◽  
pp. 35
Author(s):  
Ichiko Morino ◽  
Aika Okuno ◽  
Yuka Hirakawa ◽  
Yumiko Saya ◽  
Yumi Murakami ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Normal Skin ◽  
Treatment Options ◽  
Egfr Inhibitors ◽  
Therapeutic Effects ◽  
Cutaneous Toxicity ◽  
Skin Cream ◽  
Epidermal Growth

Although epidermal growth factor receptor (EGFR) inhibitors are one of the most effective treatment options for lung cancer, they frequently cause cutaneous toxicity that can lead to treatment discontinuation. Dryness, which is a common form of cutaneous toxicity, is usually treated using medical moisturizing agents. We aimed to investigate the treatment of cutaneous toxicity caused by EGFR inhibitors by comparing patients who used a cosmetic moisturizer with those who used conventional medical moisturizers. This study included 12 patients with lung cancer, who were receiving EGFR inhibitors and using topical medical moisturizers. The participants were assigned to a group that continued using medical moisturizers or a group that began using NOV® skin cream D. The study’s findings showed that like conventional medical moisturizers, NOV®skin cream D improved the cutaneous dryness caused by EGFR inhibitors and that it might additionally improve patients’ quality of life. Also, we obtained novel findings that NOV® skin cream D normalized keratinization, which is a component of normal skin cell differentiation impeded by EGFR inhibitors. Hence, the cosmetic moisturizer may help to prevent the discontinuation of EGFR inhibitors, thereby ensuring their continuous therapeutic effects.

A pilot crossover study to evaluate the use of Regenecare topical wound gel in patients with cutaneous toxicity caused by epidermal growth factor receptor (HER1/EGFR) inhibitors

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 19643-19643
Author(s):  
S. Wong ◽  
K. E. Osann ◽  
K. P. Lloyd ◽  
C. M. Vasko ◽  
R. L. Arcinas ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Skin Rash ◽  
Clinical Symptoms ◽  
Growth Factor Receptor ◽  
Egfr Inhibitors ◽  
Cutaneous Toxicity ◽  
The Face ◽  
Epidermal Growth

19643 Background: Acneform rash, including pain and pruritus, presents as a dose-limiting toxicity for HER1/EGFR (epidermal growth factor receptor) inhibitors which can lead to secondary skin infection. Antibiotics and corticosteroids are treatment options with minimal or moderate success. Better rash management is desirable for optimal use of these agents. Regenecare™ Gel contains 2% lidocaine for local pain management, marine collagen to promote tissue formation, aloe vera to promote circulation and emollient effect, and sodium alginate to absorb exudates. This study evaluates the effectiveness of Regenecare™ Gel in relieving the clinical symptoms of HER1/EGFR inhibitors-induced skin rash. The secondary objective assesses patient tolerability and satisfaction. Methods: A single center, prospective pilot cross- over study of 10–15 cancer patients treated with HER1/EGFR inhibitor. At the occurrence of grade 2 skin rash, subjects who signed an informed consent started applying study gel on the right side of the face and then crossed-over to both sides of the face after 1 week. Subjects were examined weekly for facial evaluations and photographs. The study continued for a total of six weeks. Results: Eight patients were enrolled with 6 evaluable (3 cetuximab, 2 panitumumab, 1 erlotinib). A summary of the itch and pain score responses are outlined below. Comparative analysis for Treatment vs. No Treatment show significant improvement with respect to self-reported level of itch (p=0.019) and pain (p=0.033). All patients tolerated the study gel without any adverse effect and 5 patients were very satisfied with the effectiveness of the gel. Conclusions: Regenecare™ Gel appears effective in relieving EGFR inhibitors rash-associated pruritus and pain based on these preliminary analyses. Study is ongoing for further assessment. No significant financial relationships to disclose. [Table: see text]

scholarly journals EGFR Signaling and its inhibition by EGFR inhibitors in NSCLC

2014 ◽  
Vol 2 (4) ◽  
pp. 375-388
Author(s):  
Rajvi Patel
Keyword(s):  
Lung Cancer ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Intracellular Signaling ◽  
Growth Factor Receptor ◽  
The United States ◽  
Egfr Inhibitors ◽  
Growth And Survival ◽  
Over Expression ◽  
Epidermal Growth

Lung cancer is the third most cancer among the population. The American society’s estimation for lung cancer in the United States for 2014 states that about 2,24,210 people are suffering from the lung cancer and 1,59,260 deaths are occur from lung cancer. Among all the types of lung cancer, NSCLC (Non-Small cell Lung Cancer) represents 85% of the lung cancer. The estimated spread of NSCLC is 2,26,160 and 1,60,340 cases are of death in 2012. One of the risk factor for NSCLC is over expression of epidermal growth factor receptor (EGFR) and its intracellular signaling pathways. EGFR is over expressed in 40-80 % cases of NSCLC. EGFR belongs to the ErbB family of receptor tyrosinekinases (RTK) having molecular weight 170 to 185 kDa. Epidermal Growth Factor (EGF) binds to the EGFR at its extracellular domain and this binding leads to the homo or hetero dimerization and autophosphorylation of EGFR which initiates the several intracellular pathways. Several mutations in EGFR or in any of the proteins of the pathway leads to the growth and survival of the tumor cells. So in order to inhibit the growth of tumor cell, several EGFR inhibitors and targeted therapies are found to target the particular mutations.DOI: http://dx.doi.org/10.3126/ijasbt.v2i4.11263 Int J Appl Sci Biotechnol, Vol. 2(4): 375-388 

Sign in / Sign up

Export Citation Format

Share Document